Clean cap tables beat high valuations every time
How to take seed money on terms that fund you without governing you, so the round you need in two years is a round you can actually raise.
Food Edge
Food Edge - the food biotech intelligence that prevents investment disasters. Every Tuesday, Thursday and Saturday: product market fit, manufacturing reality checks, regulatory and technical assessments that help founders win.
Subscribe:.rss.atom.json.md.m3u.pls
Live Last read · last published · next check
Latest episodes
Saves to your Listen queue, to pick up on another day or another device.
The seed cap-table veto that VCs never mention.
he seed terms a founder signs to survive the year are the same terms that quietly veto the round he needs two years later. Nobody reads them out loud until it is too late to change them.
Your runway is a hall of mirrors
The math of survival most B2B Food Biotech founders refuse to calculate until it is ninety days too late.
The five things that actually kill food biotech companies
Five recurring causes of death. Each one named, each one preventable, none of them new. Thursday's antidote to Tuesday's diagnosis.
You don't have a startup. You have a project.
The diagnosis most founders and investors get wrong, and pay for twice.
What investors aren't saying when they pass
The 7 unsaid reasons your round didn't close, and the self test for each
Plant-based 2.0 will be won in texture labs, not marketing teams
The next great plant-based company will look less like a marketing team with a cause and more like a texture lab with a P&L.
The sensory data room: what investors need to see before they believe your consumer story.
An audit framework for the evidence base behind any product claim that depends on taste, texture, preference, satiety, or repeat behaviour. The deck talks. The data room closes.
Corporate pilot purgatory - how to tell if a pilot can actually become revenue
Every pilot signature lives inside two rooms. Founders only see one. The other - procurement, quality, operations, finance, legal - is where pilots die.
The industry has been measuring the wrong thing with the wrong dataset
The data that matters has been sitting in sensory panels and store loyalty feeds all along.
Why most Food Biotech platforms should start as ingredient companies
Platforms are earned, not announced. The path to becoming one runs through shipping a single ingredient first.
What 2026 funding is rewarding now
Real science, real revenue, fewer fantasies
Your precision fermentation startup does not have a moat. Downstream processing does.
The molecule story is overexposed. The recovery story is underexposed. Where value and defensibility actually sit in the precision fermentation value chain.
The best Food Biotech startups will rent before they build
When renting fermentation capacity is smarter, when ownership becomes justified, and the 10-question checklist that tells you which stage you are actually in.
The real bottleneck is scale-up, not science
Why most FoodBioTech value is lost after the raise, in the transfer, and what transfer-grade evidence actually looks like before an investor asks for it.
Silicon Valley is the worst place to build a FoodBioTech startup
Why CEE and boring industrial geographies will own the infrastructure decade, and what a TEA-honest location decision actually looks like.
Your cost curve is theatre. Here is what investors actually underwrite.
Precision fermentation will reach 267 billion USD by 2035. Every deck in the room has a beautiful ski slope. None of them have an empirical spine.
Fantasy math: What the eFishery, Believer and Meatable collapses tell FoodBioTech founders
Three collapses. One pattern. The decision architecture failure that is inside more companies than anyone wants to admit.
74% of all food innovations require the same 3 moves and why your 2035 roadmap has a 2028 problem
100,000 simulations. Six scenarios. One convergence. The companies that win the next decade are not betting on which future wins
Your IP is only 15% of your exit value
Patents and technology are not what acquirers pay for. Here is the breakdown - and the CEE founder trap it creates.